Investor Presentation

**Investor Presentation Summary** 1. **Financial Highlights**: For the fiscal year 2023, the company reported revenues of ₹6,282 crore with an EBITDA margin of 13.1%. Projections for TTM December 2024 show an increase to ₹7,064 crore and an improved EBITDA margin of 16.3%. The goal is to reach ₹13,500 crore revenue with a margin of 23%-25% by FY30. 2. **Strategic Initiatives and Growth Drivers**: Key growth areas include Radiopharmaceuticals, CDMO-Sterile Injectables, and Allergy Immunotherapy.

The company plans to double CRDMO capacity in the US while expanding its presence in high-margin specialties and PET radiopharmacies.

3. **Business Developments**: The recent focus is on enhancing drug discovery services and doubling capacity in various segments.

Partnerships with large pharma are expected to bolster revenues significantly over the coming years.

4. **Market Position and Competitive Advantage**: Jubilant Pharmova maintains a strong competitive edge in North America, particularly in Radiopharmaceuticals and Allergy Immunotherapy.

It aims to leverage its quality reputation and extensive global network.

5. **Investor Implications**: Investors should note the company's ambitious targets amidst a supportive market environment, indicating a positive outlook.

The drive for innovation, coupled with a strong operational framework, positions it favorably for growth, making it a potential market player to watch closely.